20th European AIDS Conference October 15th-18th , 2025 Paris, France

Conference Reports for NATAP


20th European AIDS Conference October 15th-18th , 2025 Paris, France

	Real-world implementation of long-acting injectable cabotegravir and rilpivirine: healthcare providers' perspectives and experiences - (11/04/25) The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB + RPV LA After Rapid Suppression With DTG/3TC - (11/04/25) Healthcare Utilization and Costs in People Living with HIV With and Without Hypertension and Type 2 Diabetes Mellitus in the United States - (11/04/25) High Risk of Renal Complications After Type 2 Diabetes Mellitus Diagnosis in People with HIV Compared with People Without HIV: Findings From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) - (11/04/25) Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway - (11/04/25) USE OF PCSK9 INHIBITOR EVOLOCUMAB IN PLWH WITH PERSISTENT HYPERLIPIDEMIA DESPITE STATIN THERAPY: TWO CASE REPORTS - (11/04/25) A Comparative Analysis of Echocardiographic Findings in People Living With HIV and Healthy Volunteers - (11/04/25) Bempedoic acid and evolocumab use in [older] people living with HIV [multimorbodity]: A real-world snapshot of lipid-lowering strategies in statin-intolerant or reluctant individuals - (11/04/25) Are we implementing statin initiation following the REPRIEVE Trial: Results of a clinical audit at an urban sexual health clinic in Sydney, Australia - (11/04/25) Are we implementing statin initiation following the REPRIEVE Trial: Results of a clinical audit at an urban sexual health clinic in Sydney, Australia - (11/04/25) Use of statins mitigates the impact of smoking on frailty trajectories in people with HIV: a longitudinal cohort study - (11/04/25) People with HIV at high cardiovascular risk were undertreated with statins independent of gender - (11/04/25) [undiagnosed comorbidities] Systematic screening for age-related comorbidities: health care optimization among individuals living with HIV in the out-patient clinic in Copenhagen, Denmark - (11/04/25) Oral Weekly Islatravir + Lenacapavir, Efficacy, PK- Update - (10/27/25) Prostate Cancer in PLWH - Results from a Large Retrospective Multicentre Analysis in Germany - (10/25/25) Hepatitis B virus reactivation in people living with HIV switching to long acting-cabotegravir/rilpivirine therapy: a cohort study analysis - (10/25/25) Metabolic and Body Composition Outcomes at 48 Weeks among People with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide Switching to Doravirine with or without Tenofovir Disoproxil Fumarate: ACTG A5391 (the DO-IT Trial) - (10/25/25) Public Knowledge, Views, Perceptions and Attitudes towards HIV and People with HIV in Europe - Combined Results of an HIV Public Opinion Survey Conducted in 11 European Countries - (10/25/25) Doxycycline prophylaxis to prevent bacterial STIs Results of the open-label extension phase of the ANRS 174 DOXYVAC trial - (10/25/25) Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial - (10/25/25) Gilead Presents New HIV Research Data at EACS 2025 Driving Scientific Innovation in Treatment and Prevention - (10/20/25) Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection - (10/20/25) ViiV HEALTHCARE'S CLARITY STUDY SHOWS LONG-ACTING CABOTEGRAVIR MORE ACCEPTABLE THAN LENACAPAVIR INJECTIONS AFTER A SINGLE DOSE, WITH 90% PREFERRING CABOTEGRAVIR - (10/20/25) Evaluation of Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Randomized Phase 3 Studies in Adults Living With HIV-1 - (10/20/25) Pharmacokinetics and Safety of MK-8527 in Adults With Moderate or Severe Renal Impairment - (10/20/25) Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results - (10/20/25) Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals - (10/20/25) High In Vitro Resistance Barrier for the Bictegravir + Lenacapavir Combination - (10/20/25) Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study - (10/20/25) Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual-Modality Injections for HIV Treatment: People With HIV and Staff Perspectives - (10/20/25) Population Pharmacokinetics, Antidrug Antibodies and Exposure-Response of VH3810109 (N6LS) in Virologically Suppressed Adults Living With HIV From the Phase 2b EMBRACE Study - (10/20/25) Pharmacokinetics and Safety Data After Switching From Injectable CAB + RPV to Oral B/F/TAF - (10/20/25) Five-Year Extended Follow-Up of the Observational BICSTaR Cohort: Final Analysis in People With HIV Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Routine Clinical Practice - (10/20/25) Drug-Drug Interaction Liability of BIC/LEN Compared With Representative Complex Antiretroviral Therapy Regimens in the Phase 3 Portion of ARTISTRY-1 - (10/20/25) Weight and Body Composition After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily From BIC/FTC/TAF in Adults Living With HIV-1: Week 48 Results From a Randomized, Double-Blind Phase 3 Study - (10/20/25) Safety and Analytical Treatment Interruption Outcomes in a Clinical Trial of 2 Broadly Neutralizing Antibodies Plus Vesatolimod in Early-Treated South African Women With Clade C HIV-1 - (10/20/25) Safety and Tolerability of N6LS Administered Intravenously or Subcutaneously: Promising Results From Part 1 of the EMBRACE Study - (10/20/25) Efficacy and Safety of a Twice-Yearly Regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 Results - (10/20/25) Fostemsavir in a real-world setting: over one year of data from the PRESTIGIO Registry - (10/20/25) Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1: 96 Week Outcomes from a Phase 2 Study - (10/20/25) Commonly Prescribed Concomitant Medications and Clinical Safety Findings With Lenacapavir for Pre-Exposure Prophylaxis in PURPOSE 2 - (10/20/25) Recruitment of Disproportionately Affected Populations in the PURPOSE 5 Study Evaluating Lenacapavir for PrEP in France and the UK - (10/20/25) Annual Persistence to Twice-Yearly Lenacapavir Versus Daily Oral F/TDF for PrEP in the PURPOSE 2 Trial - (10/20/25) Health-related quality of life in ageing people with HIV is not different to that of well-matched controls without HIV: an 8-year longitudinal analysis from the AGEhIV cohort study on ageing and comorbidities - (10/20/25) Four years frailty transitions in elderly adults living with HIV: Results from the ANRS EP66 SEPTAVIH study - (10/20/25) Screening for bone health in older people with HIV: uptake and outcomes from a large UK outpatient HIV service - (10/20/25) Neurocognitive Impairment in Older People Living with HIV: Preliminary Findings from a Geriatric Care Program - (10/20/25) ViiV Healthcare showcases breadth of clInIcal and real-world evIdence at EACS and IDWeek 2025 - (10/20/25)